Oklahoma Blood Institute

“FORM 990, PART VI, SECTION B, QUESTION 11B The Oklahoma Blood Institute (OBI) has the annual IRS from 990 reviewed by two standing committees of the Board of Directors in a joint meeting with the company's external auditors prior to filing. The committees responsible for the review are the Nominating/Corporate Governance Committee and Audit/Risk Management Committee. Members of the committees receive a copy of the 990 prior to the meeting and key sections on governance, policies, compensation and program expenses are reviewed. The review is completed and the meeting documented with minutes, which become part of both committees' permanent files. At the conclusion of this review, the entire board is provided a copy of the 990 prior to filing.”

“FORM 990, PART III, QUESTION 4D These other program services are blood product derivatives. Derivatives are a product manufactured from a raw material byproduct OBI supplies to plasma manufacturers made into a biological drug. Once returned to OBI, derivatives are used for therapeutic treatments for critically ill patients. Associated revenue is $601,233. Other miscellaneous revenue in the amount of $765,625 comes from other sources directly related to the tax-exempt purpose of the organization.”

“Form 990, Part VI, Section b, Question 12c OBI's conflict of interest policy is provided to all Board members and Officers on an annual basis and they are required to sign annual conflict of interest and confidentiality statementS each year. Executed copies of the conflict of interest and confidentiality statements are maintained in the corporate records and the Chair of the Audit/Risk Management Committee and Executive Committee are informed of any conflicts disclosed. If a conflict did exist, the member would recuse themselves from any votes or discussions related to the area of conflict. OBI maintains a confidential disclosure hot line and web site that allows employees to anonymously report any concerns or potential conflict of interests. All reports are sent thru the senior H.R. employee, and significant issues are forwarded to the Chair of the Audit/Risk Management Committee.”

“Form 990, Part VI, Section c, Questions 15a & 15b The compensation of the CEO is determined by the Executive Committee of the Board of Directors comprising community leaders, business executives and physicians with exemplary ethical and fiduciary standards. CEO compensation is based on comparative salary data from similar health care organizations using IRS Form 990 and industry salary surveys. Similarly, compensation for executives reporting to the CEO is proposed by the CEO based on comparable national and local salaries for positions and approved by the Executive Committee. Changes to compensation are reviewed and formally approved by the Executive Committee of the Board of Directors. The roles of CEO and other physicians and executives requires a rare blend of astute organizational leadership, capable of providing vision and fiduciary management of the state's largest biopharmaceutical, a 700-plus staff entity, and advanced medical specialization and expertise in the unique scientific field of transfusion medicine. Executives have responsibility for 14 operational facilities across 9 major markets in the region and the day-to-day provision of safe and sufficient blood to meet the needs of patients in more than 160 hospitals served.”

“Form 990, Part VI, Section C, Question 19 Copies of the organization's form 990 are available to the public upon request and at the Guidestar.org web site. Conflict of interest and financial statements are available up on request.”

“FORM 990, PART VI, Section A, QUESTIONS 6, 7A, & 7B The Oklahoma Blood Institute's bylaws provide for a single member, OBI Holding Company, and the single member has the authority to appoint Board Members. The Single Member's board is elected by the Board of The Oklahoma Blood Institue, and their actions are subject to OBI's approval.”